尤瑞克林治疗急性脑梗死的疗效及对血管内皮生长因子水平的影响

Efficacy of Human Urinary Kallidinogenase in Treatment of Acute Cerebral Infarction and Its Effect on Vascular Endothelial Growth Factor Level

目的:探讨尤瑞克林治疗急性脑梗死的疗效及对血管内皮生长因子(VEGF)水平的影响。方法:选取2014年10月—2016年10月收治的急性脑梗死患者98例,以随机数字表法分为对照组和观察组,每组各49例,其中对照组患者采用常规治疗,观察组患者在对照组基础上加用尤瑞克林。检测治疗前后两组患者VEGF水平、美国国立卫生院卒中神经功能缺损评分量表(national institutes of health stroke scale,NIHSS),并评估治疗效果。结果:与治疗前比较,治疗后两组患者血清VEGF水平均显著升高、NIHSS评分均显著降低,而观察组变化幅度明显大于对照组,差异均有统计学意义(P<0.05);观察组总有效率为87.76%(43/49),显著高于对照组的69.39%(34/49),差异有统计学意义(P<0.05);两组患者不良反应发生率的差异无统计学意义(P>0.05)。结论:尤瑞克林可明显改善急性脑梗死患者的祌经功能,提高血清VEGF水平,对缺血脑组织具有保护作用,且无严重不良反应,值得推荐。

OBJECTIVE：To probe into the efficacy of human urinary kallidinogenase in treatment of acute cerebral infarction（ACI） and its effect on vascular endothelial growth factor （VEGF） level. METHODS： 98 patients with acute cerebral infarction from Oct. 2014 to Oct. 2016 were selected and divided into control group and observation group via random number table, with 49 cases each group. The control group was given routine treatment, and the observation group was given human urinary kallidinogenase based on routine treatment. The levels of VEGF and the NIHSS scores of two groups were detected before and after treatment, and the therapeutic effect was evaluated. RESULTS： Compared with that of before treatment, the serum VEGF levels of two groups were significantly increased, and the NIHSS scores were ignificantly decreased after treatment, and the rangeability of the observation group was more significant than that of control group, with statistically significant difference （ P 〈 0. 05 ）. The total effective rate of the observation group （ 87. 76%, 43/49 ） was significantly higher than that of control group （69. 39%, 34/49） with statistically significant difference （ P 〈 0. 05 ）. There was no statistical significance between two groups in the incidence of adverse reactions （P 〉 0. 05）. CONCLUSIONS ： The human urinary kallidinogenase can significantly improve the neurological function and the serum VEGF levels of ACI patients, and protect the ischemic brain tissue, with no serious adverse reactions. It＇s worthy of recommendation.